Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

February 04, 2026 08:50 ET Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of 2026 Pelareorep now has Fast Track Designation for two gastrointestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastrointestinal cancers SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to pelareorep in combination with bevacizumab (Avastin ® ) and leucovorin, fluorouracil, irinotecan (“FOLFIRI”) for the treatment of patients with KRAS (“Kirsten rat sarcoma”)-mutant, microsatellite-stable (“MSS”) metastatic colorectal cancer (“mCRC”) in the second-line (“2L”) setting. As part of the Company’s increased focus on gastrointestinal cancer and analysis of the existing colorectal data set in the fall, the Company applied for and has now received Fast Track Designation. The Fast Track Designation is supported by clinical data demonstrating a 33% objective response rate (“ORR”) for pelareorep-based therapy compared to approximately 10% ORR with standard-of-care (“SOC”) in this patient population. 1 -2 In addition, pelareorep combination therapy was associated with a median progression-free survival (“PFS”) of 16.6 months, compared to 5.7 months with SOC, and a median overall survival (“OS”) of 27 months, compared to 11.2 months with SOC. 1 KRAS-mutant MSS metastatic colorectal cancer represents one of the most challenging diseases in gastrointestinal oncology, as few effective treatment options exist following first-line progression, and available immune-based therapies provide little benefit. There are an estimated 2 million new colorectal cancer cases each year globally, with an annual total addressable market of approximately $3-5 billion for the 2L KRAS-mutant MSS mCRC subgroup. 3 -7 “This designation is an important validation of our focus on pelareorep’s potential as a platform immunotherapy for gastrointestinal cancers like colorectal cancer,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Adding pelareorep to the standard-of-care in this underserved segment of colorectal cancer patients results in a doubling or tripling of critical clinical endpoints, including overall survival, progression-free survival, and objective response rate in a market that is estimated to be worth several billion dollars. Pelareorep offers the potential to help a meaningful number of patients, and I look forward to continuing to collaborate with the FDA to address this treatment gap as expeditiously as possible.” Oncolytics expects to initiate a controlled clinical study in second-line KRAS-mutant MSS mCRC comparing standard-of-care therapy alone versus standard-of-care plus pelareorep. The first clinical site is expected to be activated in March, with up to 10 additional sites anticipated to open shortly thereafter. Interim data from the study are expected by year-end. Further details regarding the study design and milestones are forthcoming. The Fast Track Designation enables more frequent meetings and communication with the FDA to ensure alignment on development plans and the collection of clinical data needed to support approval. Furthermore, clinical programs with Fast Track Designation may be eligible for Accelerated Approval and Priority Review if relevant criteria are met. For conditions where an available treatment exists, a candidate therapy regimen must show some advantage over the available treatment, such as superior effectiveness, to be granted Fast Track Designation. References Bennouna J. Lancet Oncol (14):29-37, 2013 Iwamoto S. Ann Oncol. Jul;26(7):1427-33, 2015 International Agency for Research on Cancer. (n.d.). Colorectal cancer . World Health Organization – IARC. https://www.iarc.who.int/cancer-type/colorectal-cancer/ Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3. PMID: 18316791 Cohen R, et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942. PMID: 30452494; PMCID: PMC6459114. Snider J, et al. Metastatic colorectal cancer (mCRC) treatment patterns in the Medicare population. J Clin Oncol. 2018;36(4_suppl):823. https://doi.org/10.1200/JCO.2018.36.4_suppl.823 American Health & Drug Benefits. (2013). Metastatic colorectal cancer: Treatment patterns and costs . https://ahdbonline.com/issues/2013/february-2013-vol-6-no-1-special-issue/article-1294 About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.ir.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @ oncolytics . Forward-looking statements This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the anticipated design, timelines, milestones, and outcomes of current and future studies; the estimated size of the total addressable market of the 2L KRAS-mutant MSS mCRC subgroup; expected benefits of the Fast Track Designation, including increased collaboration with regulatory bodies; the Company’s goals, strategies, and objectives; and its belief in the clinical promise of pelareorep in colorectal and other gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Owen Blaschak LifeSci Communications [email protected] View All Press Releases 4350 Executive Drive Suite 325 San Diego, CA 92121 [email protected] Company Our Mission Leadership Board of Directors Careers Contact Science Our Science Pipeline Resources Investors Overview News Events Stock Information Filings Corporate Governance FAQs Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent Copyright © 2026 Oncolytics Biotech Inc. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/lsc-wp-theme-main/*","/wp-content/themes/astra/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} <div class="wcc-consent-container wcc-hide" role="complementary"> <div class="wcc-consent-bar" data-tag="notice" style="background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-notice"> <p id="wcc-title" class="wcc-title" data-tag="title" role="heading" aria-level="1" aria-labelledby="wcc-title" style="color:#212121"></p><div class="wcc-notice-group"> <div id="wcc-notice-des" class="wcc-notice-des" data-tag="description" aria-describedby="wcc-notice-des" style="color:#212121"> <p>We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.</p> </div><div class="wcc-notice-btn-wrapper" data-tag="notice-buttons"> <button class="wcc-btn wcc-btn-customize" aria-label="Customize" data-tag="settings-button" style="color:#001958;background-color:transparent">Customize</button> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Reject All</button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Accept All</button> </div></div></div></div></div><div class="wcc-modal" role="dialog" aria-label="Privacy Overview"> <div class="wcc-preference-center" data-tag="detail" style="color:#212121;background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-preference-header"> <span id="wcc-preference-title" class="wcc-preference-title" data-tag="detail-title" role="heading" aria-level="1" aria-labelledby="wcc-preference-title" style="color:#212121">Privacy Overview</span> <button class="wcc-btn-close" aria-label="Close cookie preference modal" data-tag="detail-close"> <img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/close.svg" alt="Close"> </button> </div><div class="wcc-preference-body-wrapper"> <div class="wcc-preference-content-wrapper" data-tag="detail-description" style="color:#212121"> <p>This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.</p> </div> <div class="wcc-google-privacy-policy" data-tag="google-privacy-policy"> </div><div class="wcc-accordion-wrapper" data-tag="detail-categories"> <div class="wcc-accordion" id="wccDetailCategorynecessary" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Necessary" data-tag="detail-category-title" style="color:#212121">Necessary</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchnecessary"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>wt_consent</div></li><li><div>Duration</div><div>1 year</div></li><li><div>Description</div><div>Used for remembering users’ consent preferences to be respected on subsequent site visits. It does not collect or store personal information about visitors to the site.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_cfuvid</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>Cloudflare sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::a</div></li><li><div>Duration</div><div>never</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::c</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>__cf_bm</div></li><li><div>Duration</div><div>1 hour</div></li><li><div>Description</div><div>This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryanalytics" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Analytics" data-tag="detail-category-title" style="color:#212121">Analytics</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchanalytics"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gid</div></li><li><div>Duration</div><div>1 day</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store information on how visitors use a website while also creating an analytics report of the website's performance. Some of the collected data includes the number of visitors, their source, and the pages they visit anonymously.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gat_gtag_UA_*</div></li><li><div>Duration</div><div>1 minute</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store a unique user ID.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga_*</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store and count page views.</div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryperformance" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Performance" data-tag="detail-category-title" style="color:#212121">Performance</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchperformance"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>INGRESSCOOKIE</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is used for load balancing and session stickiness. This technical session identifier is required for some website features. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryadvertisement" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Advertisement" data-tag="detail-category-title" style="color:#212121">Advertisement</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchadvertisement"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>c</div></li><li><div>Duration</div><div>6 months 2 days</div></li><li><div>Description</div><div>Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.</div></li></ul></div> </div> </div> </div></div><div class="wcc-footer-wrapper"> <span class="wcc-footer-shadow"></span> <div class="wcc-prefrence-btn-wrapper" data-tag="detail-buttons"> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="detail-reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Reject All </button> <button class="wcc-btn wcc-btn-preferences" aria-label="Save My Preferences" data-tag="detail-save-button" style="color:#FFFFFF;background-color:#E8614D;border-color:#E8614D"> Save My Preferences </button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="detail-accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Accept All </button> </div><div style="padding: 8px 24px;font-size: 12px;font-weight: 400;line-height: 20px;text-align: right;border-radius: 0 0 6px 6px;direction: ltr;justify-content: flex-end;align-items: center;background-color:#EDEDED;color:#293C5B" data-tag="detail-powered-by"> Powered by <a target="_blank" rel="noopener" href="https://www.webtoffee.com/product/gdpr-cookie-consent" style="margin-left: 5px;line-height: 0"><img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/webtoffee.svg" alt="Webtoffee logo" style="width: 78px;height: 13px;margin: 0"></a> </div></div></div></div><div class="wcc-overlay wcc-hide"></div> Secret Link ( () => { const lazyloadRunObserver = () => { const lazyloadBackgrounds = document.querySelectorAll( `.e-con.e-parent:not(.e-lazyloaded)` ); const lazyloadBackgroundObserver = new IntersectionObserver( ( entries ) => { entries.forEach( ( entry ) => { if ( entry.isIntersecting ) { let lazyloadBackground = entry.target; if( lazyloadBackground ) { lazyloadBackground.classList.add( 'e-lazyloaded' ); } lazyloadBackgroundObserver.unobserve( entry.target ); } }); }, { rootMargin: '200px 0px 200px 0px' } ); lazyloadBackgrounds.forEach( ( lazyloadBackground ) => { lazyloadBackgroundObserver.observe( lazyloadBackground ); } ); }; const events = [ 'DOMContentLoaded', 'elementor/lazyload/observe', ]; events.forEach( ( event ) => { document.addEventListener( event, lazyloadRunObserver ); } ); } )(); var astra = {"break_point":"1024","isRtl":"","is_scroll_to_id":"","is_scroll_to_top":"","is_header_footer_builder_active":"1","responsive_cart_click":"flyout","is_dark_palette":""}; //# sourceURL=astra-theme-js-js-extra jQuery.uiBackCompat = true; //# sourceURL=jquery-ui-core-js-before jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":1,"isRTL":false});}); //# sourceURL=jquery-ui-datepicker-js-after var astraAddon = {"is_elementor_active":"1","sticky_active":"1","svgIconClose":"\u003Cspan class=\"ast-icon icon-close\"\u003E\u003Csvg viewbox=\"0 0 512 512\" aria-hidden=\"true\" role=\"img\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" width=\"18px\" height=\"18px\"\u003E\n \u003Cpath d=\"M71.029 71.029c9.373-9.372 24.569-9.372 33.942 0L256 222.059l151.029-151.03c9.373-9.372 24.569-9.372 33.942 0 9.372 9.373 9.372 24.569 0 33.942L289.941 256l151.03 151.029c9.372 9.373 9.372 24.569 0 33.942-9.373 9.372-24.569 9.372-33.942 0L256 289.941l-151.029 151.03c-9.373 9.372-24.569 9.372-33.942 0-9.372-9.373-9.372-24.569 0-33.942L222.059 256 71.029 104.971c-9.372-9.373-9.372-24.569 0-33.942z\" /\u003E\n \u003C/svg\u003E\u003C/span\u003E","hf_account_show_menu_on":"hover","hf_account_action_type":"link","hf_account_logout_action":"link","header_main_stick":"1","header_above_stick":"0","header_below_stick":"0","stick_header_meta":"","header_main_stick_meta":"","header_above_stick_meta":"","header_below_stick_meta":"","sticky_header_on_devices":"desktop","sticky_header_style":"none","sticky_hide_on_scroll":"1","break_point":"1024","tablet_break_point":"1024","mobile_break_point":"767","header_main_shrink":"","header_animation_effect":"none","header_logo_width":"","responsive_header_logo_width":{"desktop":180,"tablet":"","mobile":"","desktop-svg-height":42},"stick_origin_position":"","site_layout":"","site_content_width":"1680","site_layout_padded_width":"1200","site_layout_box_width":"1200","header_builder_active":"1","component_limit":"10","is_header_builder_active":"1"}; //# sourceURL=astra-addon-js-js-extra var elementorFrontendConfig = {"environmentMode":{"edit":false,"wpPreview":false,"isScriptDebug":false},"i18n":{"shareOnFacebook":"Share on Facebook","shareOnX":"Share on X","pinIt":"Pin it","download":"Download","downloadImage":"Download image","fullscreen":"Fullscreen","zoom":"Zoom","share":"Share","playVideo":"Play Video","previous":"Previous","next":"Next","close":"Close","a11yCarouselPrevSlideMessage":"Previous slide","a11yCarouselNextSlideMessage":"Next slide","a11yCarouselFirstSlideMessage":"This is the first slide","a11yCarouselLastSlideMessage":"This is the last slide","a11yCarouselPaginationBulletMessage":"Go to slide"},"is_rtl":false,"breakpoints":{"xs":0,"sm":480,"md":521,"lg":1025,"xl":1440,"xxl":1600},"responsive":{"breakpoints":{"mobile":{"label":"Mobile Portrait","value":520,"default_value":767,"direction":"max","is_enabled":true},"mobile_extra":{"label":"Mobile Landscape","value":880,"default_value":880,"direction":"max","is_enabled":false},"tablet":{"label":"Tablet Portrait","value":1024,"default_value":1024,"direction":"max","is_enabled":true},"tablet_extra":{"label":"Tablet Landscape","value":1200,"default_value":1200,"direction":"max","is_enabled":true},"laptop":{"label":"Laptop","value":1366,"default_value":1366,"direction":"max","is_enabled":true},"widescreen":{"label":"Widescreen","value":1901,"default_value":2400,"direction":"min","is_enabled":true}},"hasCustomBreakpoints":true},"version":"4.3.2","is_static":false,"experimentalFeatures":{"additional_custom_breakpoints":true,"container":true,"nested-elements":true,"import-export-customization":true,"e_pro_atomic_form":true,"e_pro_collection_loop":true},"urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor\/assets\/","ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","uploadUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/uploads"},"nonces":{"floatingButtonsClickTracking":"d73e02d1ff","atomicFormsSendForm":"f93f7be7be"},"swiperClass":"swiper","settings":{"page":[],"editorPreferences":[]},"kit":{"active_breakpoints":["viewport_mobile","viewport_tablet","viewport_tablet_extra","viewport_laptop","viewport_widescreen"],"viewport_widescreen":1901,"viewport_mobile":520,"global_image_lightbox":"yes","lightbox_enable_counter":"yes","lightbox_enable_fullscreen":"yes","lightbox_enable_zoom":"yes","lightbox_enable_share":"yes","lightbox_title_src":"title","lightbox_description_src":"description"},"post":{"id":7298,"title":"Oncolytics%20Biotech%C2%AE%20Receives%20FDA%20Fast%20Track%20Designation%20for%20Pelareorep%20in%202L%20KRAS-Mutant%20MSS%20Metastatic%20Colorectal%20Cancer%20%7C%20Oncolytics%20Biotech%20Inc.","excerpt":"","featuredImage":false}}; //# sourceURL=elementor-frontend-js-before wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var ElementorProFrontendConfig = {"ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","nonce":"63851120d4","urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/assets\/","rest":"https:\/\/ir.oncolyticsbiotech.com\/wp-json\/"},"settings":{"lazy_load_background_images":true},"popup":{"hasPopUps":false},"shareButtonsNetworks":{"facebook":{"title":"Facebook","has_counter":true},"twitter":{"title":"Twitter"},"linkedin":{"title":"LinkedIn","has_counter":true},"pinterest":{"title":"Pinterest","has_counter":true},"reddit":{"title":"Reddit","has_counter":true},"vk":{"title":"VK","has_counter":true},"odnoklassniki":{"title":"OK","has_counter":true},"tumblr":{"title":"Tumblr"},"digg":{"title":"Digg"},"skype":{"title":"Skype"},"stumbleupon":{"title":"StumbleUpon","has_counter":true},"mix":{"title":"Mix"},"telegram":{"title":"Telegram"},"pocket":{"title":"Pocket","has_counter":true},"xing":{"title":"XING","has_counter":true},"whatsapp":{"title":"WhatsApp"},"email":{"title":"Email"},"print":{"title":"Print"},"x-twitter":{"title":"X"},"threads":{"title":"Threads"}},"facebook_sdk":{"lang":"en_US","app_id":""},"lottie":{"defaultAnimationUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/modules\/lottie\/assets\/animations\/default.json"}}; //# sourceURL=elementor-pro-frontend-js-before /(trident|msie)/i.test(navigator.userAgent)&&document.getElementById&&window.addEventListener&&window.addEventListener("hashchange",function(){var t,e=location.hash.substring(1);/^[A-z0-9_-]+$/.test(e)&&(t=document.getElementById(e))&&(/^(?:a|select|input|button|textarea)$/i.test(t.tagName)||(t.tabIndex=-1),t.focus())},!1);

The release as fetched from its publisher. oncolyticsbiotech.com ↗